Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
- PMID: 16642044
- DOI: 10.1038/sj.leu.2404246
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
Abstract
In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis. We determined FLT3 internal tandem duplications (FLT3/ITD) and D835 point mutations in paired initial and relapse samples from 80 pediatric and adult AML patients. One D835 point mutation was found in an initial pediatric AML sample. Fms-like tyrosine kinase 3/ITDs were present in 21 initial and 22 relapse samples (26.3 and 27.5%, respectively). Interestingly, FLT3/ITD positivity was related to a significantly shorter time to relapse, most pronounced when the ITD-positive status was found at relapse (P<0.001). However, FLT3/ITD status changed between diagnosis and relapse in 14 cases. In four patients, the FLT3/ITD became undetectable at relapse in five patients FLT3/ITDs were only detected at relapse, and in five patients the length or number of FLT3/ITDs changed. Gain of FLT3/ITDs may suggest oligoclonality with selective outgrowth of the FLT3/ITD-positive clone, whereas losses may reflect ITDs in the more mature leukemic cells rather than in the leukemic stem cell, or, alternatively, that other genetic aberrations provided a greater selective advantage. Studying FLT3/ITD kinetics in minimal residual disease setting may provide some answers for the changes we observed. Fms-like tyrosine kinase 3/ITD is a relevant marker for prognosis, and remains an important target for therapeutic inhibition.
Similar articles
-
Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.Leuk Res. 2004 Oct;28(10):1069-74. doi: 10.1016/j.leukres.2004.02.009. Leuk Res. 2004. PMID: 15289019
-
Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.Ann Hematol. 2007 Oct;86(10):741-7. doi: 10.1007/s00277-007-0325-3. Epub 2007 Jun 20. Ann Hematol. 2007. PMID: 17579862
-
Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.Ann Hematol. 2009 Nov;88(11):1089-97. doi: 10.1007/s00277-009-0733-7. Epub 2009 Mar 19. Ann Hematol. 2009. PMID: 19296110
-
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.Expert Rev Hematol. 2014 Apr;7(2):301-15. doi: 10.1586/17474086.2014.857596. Epub 2013 Dec 6. Expert Rev Hematol. 2014. PMID: 24308526 Review.
-
[FLT3 Mutations in Acute Myeloid Leukemia].Rinsho Byori. 2017 Jan;65(1):44-51. Rinsho Byori. 2017. PMID: 30695511 Review. Japanese.
Cited by
-
New approaches for the detection of minimal residual disease in acute myeloid leukemia.Curr Hematol Malig Rep. 2007 May;2(2):111-8. doi: 10.1007/s11899-007-0016-0. Curr Hematol Malig Rep. 2007. PMID: 20425359 Review.
-
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment.Int J Mol Sci. 2019 Jan 8;20(1):228. doi: 10.3390/ijms20010228. Int J Mol Sci. 2019. PMID: 30626126 Free PMC article. Review.
-
Minimal Residual Disease in Acute Myeloid Leukemia.Curr Treat Options Oncol. 2017 Jan;18(1):1. doi: 10.1007/s11864-017-0447-3. Curr Treat Options Oncol. 2017. PMID: 28110381 Review.
-
Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.Front Oncol. 2020 Nov 2;10:596134. doi: 10.3389/fonc.2020.596134. eCollection 2020. Front Oncol. 2020. PMID: 33224890 Free PMC article. Review.
-
Clonal evolution of acute leukemia genomes.Oncogene. 2013 Jan 10;32(2):135-40. doi: 10.1038/onc.2012.48. Epub 2012 Feb 20. Oncogene. 2013. PMID: 22349821 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
